Home About Us FAQ Policies Contact Site Map

Biotech 2008 - Life Sciences: A 20/20 Vision to 2020

Product Type: Market Research Report Publication Date: Apr 19, 2008
 
Download a sample from "The Infoshop", another service of Global Information.

SUMMARY

2007 Industry Financials, including 12 months of company financial data and market caps for the US, Europe, Canada, and Asia

Analysis of key activities across industry sectors including healthcare, personalized, predictive and, preventive medicine, wellness, ag-biotech, industrial biotechnology and biofuels

  • Highlights of the most important recent advances in technology including stem cells and nanotechnology
  • Politics and Policy - with special features on the presidential campaign and how it is likely to affect the life sciences industry
  • Analysis of deal making, the venture capital environment and capital markets.
  • The biotech industry around the world - Canada, Europe, Asia, with special features on emerging global players such as China, India, Malaysia, Brazil

TABLE OF CONTENTS

Chapter 1: 20/20 Vision to 2020

  • Our Vision
  • Healthcare
  • AgBio
  • The Global Scene
  • Business Models and Market Cap

Chapter 2: Industry Metrics

  • 2007 Snapshot
  • The Capital Markets
  • Financings
  • M&A/Partnering
  • Regulatory
  • Biofuels in the Melting Pot
  • Global Biotech Crop Area Increased
  • International
  • Burrill's Predictions for Biotech in 2008

Chapter 3: Healthcare

  • Pharma Readies for the Future
    • Modest Growth Predicted for Pharmaceutical Market
    • Mixed Year for Pharma and Biotech
    • Pharma's Top-Selling Drugs Starting to Peak
    • Steady Growth for Biotech Drugs
    • Product Approvals
    • Selected Major Setbacks in 2007
    • Innovation Gap Still Wide
    • Healthcare Spending
  • Personalized Medicine
    • Investors Wowed by Personalized Medicine
    • Diagnostics Companies Have a Good Year
    • Companion Diagnostics
    • Reimbursement is Critical
    • Dx Attracts Venture Capital and Suitors

Chapter 4: Wellness

  • Consumers Want a Quality Experience
    • Big Food Goes Healthy
    • Wall Street Performance
    • M&A
    • Investors Whet Their Appetite
    • The International Market
    • The Regulatory Arena
  • Wellness and Prevention: The New Watchwords of Healthcare
    • Nutrigenomics Advances Personalized Nutrition
  • Healthy Aging
    • Using Beauty Drugs and Foods to Slow the Advance of Time
    • Organic Becomes Mainstream
  • Targeting Obesity
    • Biotech and Pharma Weigh In
    • Functional Foods for Weight Control
  • Edible Remedies
    • Medical Foods and Plant-based Therapies
    • Functional Foods
    • Probiotics: Focus on Digestive Health
    • Supplements
  • Looking Ahead

Chapter 5: Emerging Technologies

  • Technologies Impacting Healthcare
  • Systems Biology
    • From Sequences to Systems Biology
    • Systems Biology Alters Drug Development
  • Nanomedicine
    • Nanotubes
    • Nanowires
    • Nanodiagnostics
  • NIH Roadmap 2008
    • Human Microbiome Project
    • Epigenomics
  • The Quest for the $1,000 Genome
    • The X PRIZE
    • Human Whole-Genome Sequencing
    • Illumina Sequences Genome of African Male
    • Scientists Create First Synthetic Bacterial Genome
  • The Power of RNA
    • RNA Interference-Switching Genes Off
    • RNA Activation-Switching Genes On
    • microRNA-Great Potential in Diagnostics and Treatments
  • Gene Therapy
  • Genomics: Back on the Radar Screen

Chapter 6: Politics and Policy

  • FDA Amendments Act: Higher Fees, Enhanced Safety 118
    • PDUFA IV: Booming User Fees
    • Trials Registry and Databank
    • Conflict of Interest Waivers
    • What We Talk About When We Talk About Preemption
    • Post-Vioxx: The Need for Improved Drug Safety
    • FDAAA and Safety
    • Medical Device User Fee and Modernization Act
  • Changing Landscape 126
  • Diagnostics and Devices 128
    • Genomics: The Future of Safety?
    • The Genomics and Personalized Medicine Act of 2007
    • Personalized Medicine Milestone: Warfarin
    • IVDMIAs: FDA Revises Draft Guidance
    • MammaPrint: The First
    • Report Roundup: Genetics Tests and Nanotech Draw Scrutiny from Federal Agencies
    • Other Device and Diagnostic News
  • Patents: Worrisome Patent Changes on the Horizon
    • In the Courts
    • New USPTO Rules
    • Patent Reform Legislation
    • Storm Warnings
  • Global Stem Cell Developments
    • Asia Moves Forward With Stem Cell Research
    • Other Stem Cell News
  • Asian Trends
  • An Overview of EU Developments

Chapter 7: Agbio

  • The Gene Revolution Transforms the Green Revolution
  • Companies Drive Innovation
    • Monsanto: A Long List of Deals
    • Syngenta Goes East-To China and Australia
    • Dow Goes South-To Latin America
    • DuPont: Busy Globally
    • Brazil: A Growing Player
  • Transgenics Become Mainstream
    • Global Metrics
    • Countries Move to Develop Own GM Technology
    • US Farmers Embrace Transgenics
    • Genetic Modification Taking Root in Europe-Slowly
    • The Changing Regulatory Landscape
  • Enabling Technologies
    • RNA Interference as a Pesticide
    • Bioremediation
    • Enhancing the Nutritional Quality of Food
    • Molecular Breeding, A Next-Generation Technology
    • Plant-Made Pharmaceuticals Become a Reality
    • Transgenic Animals
  • Looking Ahead

Chapter 8: Industrial Biotech and Biofuels

  • The New Bio-Economy
    • International Initiatives
    • The United States: the Energy Independence and Security Act of 2007
  • Corporate Developments
    • Companies Push into the Global Market
    • Oil Companies Get Green
    • Cleantech Fuels VC Interest
    • Alternative Energy Gets US Government Backing
  • Bioenergy
    • Ethanol
    • Cellulosic Ethanol/Biomass
    • Biodiesel
    • Algae: A Potential Next-Generation Feedstock
    • Using Synthetic Biology To Make Designer Microbes
    • Microbial Fuel Cells
    • Bioplastics
    • Integrated Biorefineries
    • Biochememicals
  • Looking Ahead

Chapter 9: International

  • Europe
  • Denmark
  • Canada
  • Australia/New Zealand
  • China
  • Japan
  • Malaysia
  • India

Chapter 10: M&A/Partnering

  • Activity Down
  • Select M&A Transactions
    • $5-Billion-plus Deals
    • $1-Billion-plus Deals
    • Specialty Sector Transactions
    • Cancer
    • Trends
    • Regional M&A
  • Partnering
    • Deal Activity
    • The Top 18
    • Regional Alliances
    • Analysis of Transactions
  • The Outlook to 2020

Chapter 11: Finance & Capital Markets

  • No Shortage of Capital for Biotechs
  • Positive Year for Biotech IPOs
  • China Connection
  • Other IPO Winners
  • On the Runway
  • PIPEs-An Essential Vehicle for Biotech
  • Follow-Ons
  • Debt
  • Venture Capital at Record Levels
  • Positive Performance on Capital Markets
  • Billion-Dollar Club
  • Burrill Mid-Cap Index
  • Burrill Small-Cap Index
  • Creative Financing and Listing Alternatives
    • Euronext
    • Biotech Platform
  • Looking Ahead
  • Industry Financial Data Reconciliation
  • Companies Ranked by December 31, 2007 Market Cap
  • Companies in Alphabetical Order

Chapter 12: About Burrill & Company

  • Burrill & Company
  • Venture Capital
  • International
    • Greater China Group
    • India Group
    • Japan Group
    • Latin America Group
    • Malaysia Group
    • Middle East Group
  • Advisory Boards
  • Large Corporate Limited Partners
  • Portfolio Companies
  • Private Equity
  • Merchant Banking
  • Media

Biotech 2008 - Life Sciences: A 20/20 Vision to 2020

Publisher: BURRILL & COMPANY

Format Price Order
Web Access (Single User License) US $295.00
Hard Copy US $430.00
Hard Copy and Web Access (Single User License) US $680.00
All orders are processed by "www.the-infoshop.com". www.the-infoshop.com is another Global Information web site. This transfer is entirely safe.
Copyright© 2008 GII - All Rights Reserved.